Abstract
Pancreatic cancer is a devastating disease characterized by almost identical incidence and mortality rates. Since this tumour is mostly diagnosed in an advanced stage there is usually no option for a curative surgical resection. In addition, pancreatic cancers known to be resistant to conventional treatment modalities such as chemotherapy and radiotherapy. Therefore, novel strategies for targeting these tumors are urgently needed. The increasing knowledge on the underlying pathogenetic mechanisms has led to the identification of surface receptor molecules that initiate intracellular signalling cascades upon ligand binding, thus leading to tumor progression. Targeting these receptors or their secreted ligands is therefore an attractive new approach for cancer therapy. The epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor receptor (VEGFR) are transmembrane tyrosine kinase receptors which can be targeted by various compounds such as antibodies or small molecule inhibitors. In addition, various molecules targeting proteins secreted by pancreatic cancers such as matrix metalloproteinases (MMP’s) or intracellular oncogenic signalling components such as the farnesyl-transferase have been proposed as potential new approaches for targeted cancer therapy. The use of these agents alone or in combination with conventional therapeutic regimens is currently being evaluated and shows first promising results for pancreatic cancer therapy.
Similar content being viewed by others
References
Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med, 1992, 326: 455–465.
Gress TM. Exocrine pancreas cancer-The European Pancreatic Cancer-Research Cooperative (EPC-RC). In: Felsenstein, Hannover, 2005, 42–59.
Yeo CJ, Cameron JL. Improving results of pancreaticoduodencectomy for pancreatic cancer. World J Surg, 1999, 23: 907–912.
Parker SL, Tong T, Bolden S, et al. Cancer statistics. CA Cancer J Clin, 1996, 46: 5–27.
Vimalachandran D, Ghaneh P, Costello E, et al. Genetics and prevention of pancreatic cancer. Cancer Control, 2004, 11: 6–14.
Casey G, Yamanaka Y, Friess H, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett, 1993, 69: 151–160.
Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res, 1997, 57: 1731–1734.
Wilentz RE, Lacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res, 2000, 60, 2002–2006.
Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol, 1993, 143: 545–554.
Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature, 1984, 309: 418–425.
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103: 211–225.
Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets, 2005, 5: 171–193.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19: 6550–6565.
Riely GJ, Pao W. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important? Cancer Biol Ther, 2005, 4: 1096–1097.
Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol, 2002, 29: 31–37.
Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol, 2004, 22: 2610–2616.
Krempien R, Muenter MW, Huber PE, et al. Randomized phase II-study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer-PARC: study protocol [ISRC TN56652283]. BMC Cancer, 2005, 5: 131.
Graeven U, Kremer B, Sudhoff T, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer, 2006, 94: 1293–1299.
Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother, 2006, 7: 177–193.
Li J, Kleeff J, Giese N, et al. Gefitinib (’Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol, 2004, 25: 203–210.
Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol, 2006, 24: 656–662.
Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol, 2001, 61: 253–270.
Ortega N, Jonca F, Vincent S, et al. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am J Pathol, 1997, 151: 1215–1224.
Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 1999, 13: 9–22.
Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004 7: 335–345.
Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol, 2006, 24: 1145–1151.
Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 2005, 23: 8033–8040.
Folkman J, Rogers MS. Thalidomide for multiple myeloma. N Engl J Med, 2006, 354: 2389–2390.
Villalona-Calero M, Schaaf L, Phillips G, et al. Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients. Cancer Chemother Pharmacol, 2006.
Cox MC, Dahut WL, Figg WD, et al. The use of thalidomide in androgen-independent prostate cancer. Urol Oncol, 2006, 24: 246–249.
Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut, 2005, 54: 540–545.
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099–7109.
Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res, 2006, 12: 144–151.
Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol, 2001, 19: 3447–3455.
Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer, 2001, 85: 1865–1870.
Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer, 2002, 87: 161–167.
Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs, 2005, 23: 485–487.
End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res, 2001, 61: 131–137.
Martin NE, Brunner TB, Kiel KD, et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res, 2004, 10: 5447–5454.
Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol, 2004, 22: 1430–1438.
Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control, 2004, 11: 32–38.
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol, 2005, 23: 1s.
Maples WJ, Stevenson J, Sumrall SV, et al. J Clin Oncol, 2004, 22: 4082.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michl, P., Gress, T.M. Pancreatic cancer — Outlook: targeted therapy. Chinese German J Clin Oncol 6, 176–180 (2007). https://doi.org/10.1007/s10330-007-0048-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-007-0048-x